A Randomized Phase II Study of Perioperative mFOLFIRINOX versus Gemcitabine/nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
This randomized phase II trial studies how well fluorouracil, irinotecan hydrochloride, and
oxaliplatin (combination chemotherapy) works and compares to gemcitabine hydrochloride and
paclitaxel albumin-stabilized nanoparticle formulation before surgery in treating patients
with pancreatic cancer that can be removed by surgery. Drugs used in chemotherapy, such as
fluorouracil, irinotecan hydrochloride, oxaliplatin, gemcitabine hydrochloride, and
paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the
growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. Giving more than one drug (combination chemotherapy) may kill
more tumor cells. It is not yet known whether combination chemotherapy is more effective than
gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation before
surgery in treating pancreatic cancer.
Manchester,Nashua,St. Johnsbury, VT
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.